Advertisement

Magnesium Sulfate Injection

[12 December 2014]

Products Affected - Description

Magnesium sulfate injection, American Regent
500 mg/mL, 2 mL vial (NDC 00517-2602-25)
500 mg/mL, 10 mL vial (NDC 00517-2610-25)
500 mg/mL, 50 mL vial (NDC 00517-2650-25)
 
Magnesium sulfate injection, Fresenius Kabi
500 mg/mL, 2 mL vial (NDC 63323-0064-02)
500 mg/mL, 10 mL vial (NDC 63323-0064-10)
500 mg/mL, 20 mL vial (NDC 63323-0064-20)
500 mg/mL, 50 mL vial (NDC 63323-0064-50)

Magnesium sulfate injection, Hospira
500 mg/mL, 10 mL syringe (NDC 00409-1754-10)
500 mg/mL, 20 mL vial (NDC 00409-2168-02)
40 mg/mL, 500 mL premixed bag (NDC 00409-6729-03)

Reason for the Shortage

  • American Regent has magnesium sulfate on shortage due to manufacturing delays.
  • Fresenius Kabi (formerly APP) had magnesium sulfate injection on shortage due to increased demand for the product.
  • Hospira has magnesium sulfate injection on shortage due to manufacturing delays.

Available Products

Magnesium sulfate injection, Hospira
10 mg/mL, 100 mL premixed bag (NDC 00409-6727-23)
40 mg/mL, 50 mL premixed bag (NDC 00409-6729-24)
40 mg/mL, 100 mL premixed bag (NDC 00409-6729-23)
40 mg/mL, 1000 mL premixed bag (NDC 00409-6729-09)
80 mg/mL, 50 mL premixed bag (NDC 00409-6730-13)

Estimated Resupply Dates

  • American Regent has magnesium sulfate 500 mg/mL 2 mL, 10 mL, and 50 mL vials on back order and the company cannot estimate a release date.
  • Fresenius Kabi has magnesium sulfate 500 mg/mL 20 mL and 50 mL vials on intermittent back order and the company is releasing product as it becomes available. Magnesium sulfate 500 mg/mL 2 mL and 10 mL vials are on back order and the company estimates a release date of 1st quarter 2015 for the 2 mL vials and mid-January 2015 for the 10 mL vials.
  • Hospira has magnesium sulfate 500 mg/mL 20 mL vials and 10 mL syringes on back order and the company estimates a release date of January 2015 for the vials and February 2015 for the syringes. The 40 mg/mL 500 mL premixed bags are on back order and the company estimates a release date of early-February 2015.

Safety

Clinicians should use caution when switching between magnesium presentations and brands to ensure patients receive the correct dose. Data are not available regarding the use of alternative magnesium salts for tocolytic therapy. Recommended maximum administration rates in the product labeling for magnesium chloride (2.88 grams/hour) preclude utility for tocolytic therapy.

Related Shortages

Updated

December 12, 2014; November 14, 2014; October 24, 2014; September 24, 2014; September 11, 2014; August 28, 2014; August 1, 2014; July 17, 2014; July 3, 2014; June 6, 2014; May 23, 2014; May 12, 2014; May 1, 2014; April 22, 2014; February 7, 2014; January 3, 2014; December 9, 2013; November 19, 2013; October 31, 2013; October 3, 2013; August 26, 2013; August 15, 2013; July 11, 2013; June 27, 2013; May 24, 2013; April 17, 2013; March 27, 2013; February 27, 2013; February 5, 2013; January 8, 2013; December 26, 2012; December 4, 2012; November 14, 2012; October 24, 2012; September 14, 2012; August 22, 2012; June 18, 2012; May 15, 2012; May 1, 2012; April 17, 2012; March 28, 2012; March 7, 2012; February 16, 2012; February 1, 2012; January 27, 2012; December 28, 2011; December 7, 2011; University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement